Literature DB >> 7516669

The CD40 antigen and its ligand.

J Banchereau1, F Bazan, D Blanchard, F Brière, J P Galizzi, C van Kooten, Y J Liu, F Rousset, S Saeland.   

Abstract

CD40 is an integral membrane protein found on the surface of B lymphocytes, dendritic cells, follicular dendritic cells, hematopoietic progenitor cells, epithelial cells, and carcinomas. It is a 45-50 kDa glycoprotein of 277 aa, which is a member of the tumor necrosis factor receptor superfamily. The CD40 gene maps to human chromosome 20q11-2-q13-2. CD40 binds to a ligand (CD40-L) which is an approximately 35 kDa glycoprotein of 261 aa, a member of the tumor necrosis factor superfamily. The CD40-L gene maps to human chromosome Xq24. This CD40-L is expressed on activated T cells, mostly CD4+ but also some CD8+ as well as basophils/mast cells. The CD40-L is defective in the X-linked hyper-IgM syndrome. Cross-linking of CD40 with immobilized anti-CD40 or cells expressing CD40-L induces B cells to proliferate strongly, and addition of IL-4 or IL-13 allows the generation of factor-dependent long-term normal human B cell lines and the secretion of IgE following isotype switching. Addition of IL-10 results in very high immunoglobulin production with limited cell proliferation. IL-10 induces naive B cells to produce IgG3, IgG1, and IgA1, and further addition of TGF beta permits the secretion of IgA2. Several evidences suggest that CD40-dependent activation of B cells is important for the generation of memory B cells within the germinal centers: (i) CD40 activated germinal center B cells cultured in the presence of IL-4 acquire a memory B cell phenotype, (ii) CD40 activated B cells can undergo isotype switching, (iii) the deficit of CD40-L results in the hyper-IgM syndrome characterized by lack of germinal centers in secondary lymphoid organ follicles and lack of IgG, IgA, and IgE, and (iv) CD40-L positive T cells are present in secondary follicles. Thymic epithelial cells, activated monocytes, and dendritic cells express CD40 antigen which may be involved in an enhanced cytokine production by these cells, allowing an amplification of T cell proliferation. Finally, as other members of the tumor necrosis factor receptor family have been shown to bind several ligands, it is possible that CD40 may bind other ligands that may trigger CD40 on different cell types such as hematopoietic cells or epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516669     DOI: 10.1146/annurev.iy.12.040194.004313

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  306 in total

1.  The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.

Authors:  K M Izumi; E D Cahir McFarland; A T Ting; E A Riley; B Seed; E D Kieff
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes.

Authors:  H H Lee; H Dadgostar; Q Cheng; J Shu; G Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

3.  Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

Authors:  C Chiodoni; P Paglia; A Stoppacciaro; M Rodolfo; M Parenza; M P Colombo
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

4.  Expression of the RelB transcription factor correlates with the activation of human dendritic cells.

Authors:  G J Clark; S Gunningham; A Troy; S Vuckovic; D N Hart
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 5.  Pre-priming: a novel approach to DNA-based vaccination and immunomodulation.

Authors:  H Kobayashi; A A Horner; E Martin-Orozco; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

6.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

7.  CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex.

Authors:  A Kaykas; K Worringer; B Sugden
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

Review 8.  Positive and negative roles of CD72 in B cell function.

Authors:  Hsin-Jung Wu; Subbarao Bondada
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

9.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Authors:  Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

10.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.